生物活性 | |||
---|---|---|---|
描述 | WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability). EC50 value: 0.28 uM. RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at 50 mg/kg revealed a CMAX of ~5 μM and T1/2 of ~2 h. Treatment with WS6 caused a progressive reduction of blood glucose over time, starting around 2 weeks[3]. Enhancement of human β-cell proliferation is one potential approach to restore β-cell mass to prevent and/or cure type 1 and type 2 diabetes. WS6, an IkB kinase and EBP1 inhibitor, can promote effective human β-cell proliferation[4]. WS6 did not change the proportion of insulin-positive beta cells or the expression of beta cell-specific transcription factors, suggesting that WS6 does not alter beta cell differentiation, and WS6 had no effect on human islet cell apoptosis or viability[5]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.79mL 1.76mL 0.88mL |
17.59mL 3.52mL 1.76mL |
参考文献 |
---|